{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:33:51Z","timestamp":1777858431864,"version":"3.51.4"},"reference-count":67,"publisher":"SAGE Publications","issue":"4_suppl","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:p>Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comorbidity and mortality. Treatment guidelines for bipolar mania generally recommend initiating first-line therapy with a second-generation antipsychotic or mood stabiliser, either alone or in combination. Asenapine is a second-generation antipsychotic with a unique receptor binding profile, licensed for the treatment of manic episodes in adults with bipolar I disorder. \u2018Real-world\u2019 data are needed to complement evidence from clinical trials, in order to provide clinicians with pragmatic information regarding the likely risks and benefits of using a new agent in clinical practice. Evidence from real-world case reports demonstrates that \u2013 as in clinical trials \u2013 asenapine is effective in treating mania and mixed episodes associated with bipolar I disorder, whether used as monotherapy or in combination with a mood stabiliser. It has a rapid onset of antimanic effect and an early improvement is associated with treatment outcome. Asenapine also shows promise in controlling depressive symptoms and clinically challenging mixed states. Asenapine has a favourable tolerability profile, compared with other first-line agents, having a minimal impact on weight and metabolic parameters. Asenapine should be considered a first-line treatment option for adults with bipolar I disorder.<\/jats:p>","DOI":"10.1177\/1359786813482534","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T21:37:12Z","timestamp":1364420232000},"page":"3-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of asenapine in clinical practice for the management of bipolar mania"],"prefix":"10.1177","volume":"27","author":[{"given":"Allan H","family":"Young","sequence":"first","affiliation":[{"name":"Centre for Mental Health, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo Carlo","family":"Altamura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Milan, Milan, Italy; Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital of Alava (Santiago), Vitoria, Spain; CIBERSAM (Centro de Investigaci\u00f3n Biom\u00e9dica en Red en el \u00c1rea de Salud Mental), Madrid, Spain; Kronikgune, Bilbao, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Millet","sequence":"additional","affiliation":[{"name":"Academic Department of Psychiatry, Rennes University, Rennes, France; Centre Hospitalier Guillaume R\u00e9gnier, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"bibr1-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-009-0085-2"},{"key":"bibr2-1359786813482534","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","edition":"4"},{"key":"bibr3-1359786813482534","unstructured":"American Psychiatric Association (2012) Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). DSM-5 Development. Available at: http:\/\/www.dsm5.org\/Pages\/Default.aspx (accessed 6 February 2013)."},{"key":"bibr4-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00909-4"},{"key":"bibr5-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.07.013"},{"key":"bibr6-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(12)74381-X"},{"key":"bibr7-1359786813482534","first-page":"247","volume":"8","author":"Cazorla P","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"bibr8-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00171.x"},{"key":"bibr9-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112442016"},{"key":"bibr10-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2005.11.004"},{"key":"bibr11-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002801"},{"key":"bibr12-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-7-40"},{"key":"bibr13-1359786813482534","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2012.709865"},{"key":"bibr14-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003560"},{"key":"bibr15-1359786813482534","unstructured":"European Medicines Agency (2010) Committee for Medicinal Products for Human Use (CHMP) assessment report for Sycrest\n                      \u00ae\n                      . Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001177\/human_med_001379.jsp&mid=WC0b01ac058001d124 (accessed 6 February 2013)."},{"key":"bibr16-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708009231"},{"key":"bibr17-1359786813482534","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721080-00001"},{"key":"bibr18-1359786813482534","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05483yel"},{"key":"bibr19-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102919"},{"key":"bibr20-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12003"},{"key":"bibr21-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1080\/15622970902823202"},{"key":"bibr22-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.05.021"},{"key":"bibr23-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-95"},{"key":"bibr24-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.08.001"},{"key":"bibr25-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082624"},{"key":"bibr26-1359786813482534","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4088\/JCP.v68n0407","volume":"68","author":"Henderson DC","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"bibr27-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"bibr28-1359786813482534","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4088\/JCP.0608e18","volume":"69","author":"Kane JM","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"bibr29-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2007.05.027"},{"key":"bibr30-1359786813482534","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321090-00001"},{"key":"bibr31-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf145"},{"key":"bibr32-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.21.2709"},{"key":"bibr33-1359786813482534","first-page":"757","volume":"14","author":"Laxman KE","year":"2008","journal-title":"Am J Manag Care"},{"key":"bibr34-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.1r084.x"},{"key":"bibr35-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-7006(10)70036-1"},{"key":"bibr36-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-7006(10)70037-3"},{"key":"bibr37-1359786813482534","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9089tx1cc"},{"key":"bibr38-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00748.x"},{"key":"bibr39-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00749.x"},{"key":"bibr40-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"bibr41-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.04.005"},{"key":"bibr42-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.02.004"},{"key":"bibr43-1359786813482534","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2006) Clinical Guidance 38. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Available at: http:\/\/www.nice.org.uk\/CG38 (accessed 6 February 2013)."},{"key":"bibr44-1359786813482534","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0506"},{"key":"bibr45-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100803"},{"key":"bibr46-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/026988119400800401"},{"key":"bibr47-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088439"},{"key":"bibr48-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810100100021"},{"key":"bibr49-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7177.149"},{"key":"bibr50-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.3.264"},{"key":"bibr51-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1159\/000228249"},{"key":"bibr52-1359786813482534","unstructured":"Saphris\n                      \u00ae\n                      Prescribing Information (2012) Available at US Food & Drug Administration website: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 6 February 2013)."},{"key":"bibr53-1359786813482534","volume-title":"Poster presented at the 2nd International Congress on Neurobiology, Psychopharmacology & Treatment Guidance","author":"Sapin C","year":"2011"},{"key":"bibr54-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"bibr55-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.181.1.49"},{"key":"bibr56-1359786813482534","unstructured":"Sycrest\n                      \u00ae\n                      Summary of Product Characteristics. (2012) Available at European Medicines Agency website: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001177\/human_med_001379.jsp&mid=WC0b01ac058001d124 (accessed 6 February 2013)."},{"key":"bibr57-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.748"},{"key":"bibr58-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f872f"},{"key":"bibr59-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-101"},{"key":"bibr60-1359786813482534","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04580"},{"key":"bibr61-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.12.2099"},{"key":"bibr62-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01204.x"},{"key":"bibr63-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2011.00908.x"},{"key":"bibr64-1359786813482534","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7090su1cj"},{"key":"bibr65-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.12.019"},{"key":"bibr66-1359786813482534","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12025"},{"key":"bibr67-1359786813482534","volume-title":"Poster presented at 164th Annual Meeting of the American Psychiatric Association","author":"Zhao J","year":"2011"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1359786813482534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1359786813482534","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1359786813482534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:13:00Z","timestamp":1777507980000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1359786813482534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":67,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1177\/1359786813482534"],"URL":"https:\/\/doi.org\/10.1177\/1359786813482534","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}